# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 81-90 of 2194 results.
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Status: Active, not recruiting
Last Changed: Jul 07, 2020
First Received: Mar 06, 2013
Disease(s): Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Intervention(s): R-DHAP, BR-DHAP
Locations: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Ematologia, Meldola, Forlì-Cesena, Italy
Clinica Humanitas, Rozzano, Milano, Italy
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, MI, Italy
CRO Aviano, Aviano, Pordenone, Italy
ASST Valle Olona, Gallarate, Varese, Italy
... and 20 other locations.
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Status: Unknown status
Last Changed: Sep 14, 2017
First Received: Jul 05, 2017
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide
Locations: Beijing Cancer Hosptical, Beijing, China
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
Status: Withdrawn
Last Changed: Apr 13, 2020
First Received: Oct 25, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Methotrexate, Cytarabine
Locations: Roxanne Wood, Providence, Rhode Island, United States
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Oct 31, 2019
First Received: Jul 19, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): CTA101
Locations: the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Status: Completed
Last Changed: Aug 22, 2014
First Received: Dec 26, 2011
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Fostamatinib
Locations: Research Site, Huntsville, Alabama, United States
Research Site, Denver, Colorado, United States
Research Site, New Haven, Connecticut, United States
Research Site, Sarasota, Florida, United States
Research Site, Atlanta, Georgia, United States
... and 17 other locations.
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
Status: Active, not recruiting
Last Changed: Jul 22, 2020
First Received: Jan 30, 2018
Disease(s): Lymphoma, B-Cell
Intervention(s): ET190L1 ARTEMIS™ T cells
Locations: Peking University Cancer Hospital, Beijing, China
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Status: Recruiting
Last Changed: Mar 20, 2020
First Received: Mar 20, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): C-CAR066
Locations: Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Status: Not yet recruiting
Last Changed: Aug 29, 2018
First Received: Aug 29, 2018
Disease(s): Diffuse Large B-Cell Lymphoma, Unspecified Site
Intervention(s): G-CHOP, R-CHOP
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Status: Active, not recruiting
Last Changed: Apr 06, 2020
First Received: Jul 03, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Idelalisib
Locations: Aarhus University Hospital, Aarhus C, Denmark
Odense University Hospital, Odense, Denmark
Halmstad County Hospital, Halmstad, Sweden
Linkoping University Hospital, Linköping, Sweden
Skane University Hospital, Lund, Sweden
... and 2 other locations.
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: Jul 07, 2020
First Received: Jul 07, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Zanubrutinib, Lenalidomide and Rituximab (ZR2)
Locations: Shanghai Ruijin Hospital, Shanghai, Shanghai, China